Compare GRMLW & RCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRMLW | RCD |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2022 | 2024 |
| Metric | GRMLW | RCD |
|---|---|---|
| Price | $0.22 | $20.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.2K | ★ 10.9K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $18.55 |
| 52 Week High | $0.37 | $24.45 |
| Indicator | GRMLW | RCD |
|---|---|---|
| Relative Strength Index (RSI) | 65.83 | 52.47 |
| Support Level | $0.11 | $18.55 |
| Resistance Level | $0.37 | $21.92 |
| Average True Range (ATR) | 0.04 | 0.41 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 34.04 | 90.23 |
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.